TRIUMPH Program
The data behind the paradigm shift.
Phase II and Phase III trials show a magnitude of effect previously unseen in pharmacological obesity therapy.
Headline result
-24%
Average weight loss after 48 weeks of treatment.
48 wk
Phase II treatment duration
Phase III
Ongoing TRIUMPH studies
Three generations compared
Compound, mechanism, effect size and regulatory status.
Generation 1
Semaglutid
Wegovy / Ozempic
Mono-agonistApproved by Thai FDA
Generation 2
Tirzepatid
Mounjaro / Zepbound
Dual-agonistApproved by Thai FDA
Generation 3
Retatrutid
Eli Lilly (in development)
Triple-agonistPhase III – clinical study access
Treatment available
Request a personal consultation
We offer this treatment – free initial consultation.